Gross Margin: 35.08%
Is the gross margin high or low?
The gross margin of 35.08% is in line with its 5-year average of 37.74%, near the low end of its 5-year range (32.95%–43.70%).
As of Saturday, June 27, 2026. 1.63% below its 12-month average of 35.66%.
WST Gross Margin
Reported quarterly gross margin; no daily interpolation.
WST Average Gross Margin Chart
WST Current vs Average Gross Margin Chart
WST Gross Margin Metrics
GROSS MARGIN
35.08%
GROSS MARGIN AVG TTM
35.66%
GROSS MARGIN AVG 3Y
36.16%
GROSS MARGIN AVG 5Y
37.74%
GROSS MARGIN AVG 10Y
35.50%
GROSS MARGIN AVG 15Y
34.02%
GROSS MARGIN AVG 20Y
32.57%
CURRENT VS TTM AVG
-1.63%
CURRENT VS 3Y AVG
-2.98%
CURRENT VS 5Y AVG
-7.05%
CURRENT VS 10Y AVG
-1.18%
CURRENT VS 15Y AVG
+3.13%
CURRENT VS 20Y AVG
+7.72%
WST Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.79B | 35.08% | 35.66% | 36.16% | 37.74% |
| Waters Corporation (WAT)vs › | $24.41B | 55.02% | 58.60% | 58.69% | 58.45% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.54B | 57.79% | 57.84% | 57.54% | 57.23% |
| Quest Diagnostics Incorporated (DGX)vs › | $23.23B | 33.23% | 32.39% | 33.17% | 35.04% |
| BioNTech SE (BNTX)vs › | $23.07B | 73.26% | 78.98% | 81.24% | 82.89% |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 86.58% | 88.58% | 89.63% | 90.66% |
| Moderna, Inc. (MRNA)vs › | $26.69B | 55.35% | 54.80% | 53.09% | 65.45% |
| Incyte Corporation (INCY)vs › | $22.73B | 92.48% | 92.70% | 93.10% | 93.74% |
| DexCom, Inc. (DXCM)vs › | $27.07B | 61.84% | 60.23% | 62.09% | 63.91% |
| Labcorp Holdings Inc. (LH)vs › | $22.26B | 27.79% | 27.30% | 28.39% | 31.16% |
Gross Margin Analysis
Gross Margin
35.1%
(Revenue - COGS) / Revenue
Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gross Margin FAQ
- What is the gross margin for West Pharmaceutical Services, Inc. (WST)?
- The gross margin for WST stock is 35.08%.
- Is West Pharmaceutical Services, Inc.'s gross margin high or low?
- The gross margin of 35.08% is in line with its 5-year average of 37.74%, near the low end of its 5-year range (32.95%–43.70%).
- What is the TTM average gross margin for West Pharmaceutical Services, Inc. (WST)?
- The TTM average gross margin for WST stock is 35.66%.
- What is the 3Y average gross margin for West Pharmaceutical Services, Inc. (WST)?
- The 3Y average gross margin for WST stock is 36.16%.
- What is the 5Y average gross margin for West Pharmaceutical Services, Inc. (WST)?
- The 5Y average gross margin for WST stock is 37.74%.
- What is the 10Y average gross margin for West Pharmaceutical Services, Inc. (WST)?
- The 10Y average gross margin for WST stock is 35.50%.
- What is the 15Y average gross margin for West Pharmaceutical Services, Inc. (WST)?
- The 15Y average gross margin for WST stock is 34.02%.
- What is the 20Y average gross margin for West Pharmaceutical Services, Inc. (WST)?
- The 20Y average gross margin for WST stock is 32.57%.
WST Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 35.08% |
| 2025-12-31 | 37.75% |
| 2025-09-30 | 36.49% |
| 2025-06-30 | 35.66% |
| 2025-03-31 | 33.33% |
| 2024-12-31 | 36.66% |
| 2024-09-30 | 35.51% |
| 2024-06-30 | 32.95% |
| 2024-03-31 | 33.27% |
| 2023-12-31 | 38.11% |
| 2023-09-30 | 38.73% |
| 2023-06-30 | 38.74% |
| 2023-03-31 | 37.80% |
| 2022-12-31 | 37.18% |
| 2022-09-30 | 38.97% |
| 2022-06-30 | 41.45% |
| 2022-03-31 | 39.57% |
| 2021-12-31 | 40.14% |
| 2021-09-30 | 40.83% |
| 2021-06-30 | 43.70% |
| 2021-03-31 | 40.64% |
| 2020-12-31 | 36.45% |
| 2020-09-30 | 34.82% |
| 2020-06-30 | 36.91% |
| 2020-03-31 | 33.99% |
| 2019-12-31 | 33.17% |
| 2019-09-30 | 32.32% |
| 2019-06-30 | 33.55% |
| 2019-03-31 | 33.05% |
| 2018-12-31 | 31.47% |
| 2018-09-30 | 31.39% |
| 2018-06-30 | 31.84% |
| 2018-03-31 | 32.51% |
| 2017-12-31 | 31.11% |
| 2017-09-30 | 31.56% |
| 2017-06-30 | 31.50% |
| 2017-03-31 | 34.61% |
| 2016-12-31 | 32.21% |
| 2016-09-30 | 32.15% |
| 2016-06-30 | 34.36% |
| 2016-03-31 | 34.05% |
| 2015-12-31 | 33.25% |
| 2015-09-30 | 31.44% |
| 2015-06-30 | 32.86% |
| 2015-03-31 | 32.66% |
| 2014-12-31 | 31.36% |
| 2014-09-30 | 30.88% |
| 2014-06-30 | 33.02% |
| 2014-03-31 | 30.68% |
| 2013-12-31 | 31.11% |
| 2013-09-30 | 30.87% |
| 2013-06-30 | 32.19% |
| 2013-03-31 | 32.91% |
| 2012-12-31 | 30.33% |
| 2012-09-30 | 29.76% |
| 2012-06-30 | 30.39% |
| 2012-03-31 | 31.96% |
| 2011-12-31 | 28.88% |
| 2011-09-30 | 27.72% |
| 2011-06-30 | 27.48% |
| 2011-03-31 | 29.79% |
| 2010-12-31 | 28.18% |
| 2010-09-30 | 27.52% |
| 2010-06-30 | 29.52% |
| 2010-03-31 | 29.92% |
| 2009-12-31 | 28.60% |
| 2009-09-30 | 27.69% |
| 2009-06-30 | 30.15% |
| 2009-03-31 | 28.59% |
| 2008-12-31 | 28.43% |
| 2008-09-30 | 25.76% |
| 2008-08-05 | 29.93% |
| 2008-03-31 | 30.85% |
| 2007-12-31 | 27.53% |
| 2007-09-30 | 26.49% |
| 2007-06-30 | 29.09% |
| 2007-03-31 | 31.21% |
| 2006-12-31 | 28.29% |
| 2006-09-30 | 26.92% |
| 2006-06-30 | 29.35% |
| 2006-03-31 | 30.03% |
| 2005-12-31 | 26.47% |
| 2005-09-30 | 24.12% |
| 2005-06-30 | 29.25% |
| 2005-03-31 | 31.04% |
| 2004-12-31 | 26.60% |
| 2004-09-30 | 27.12% |
| 2004-06-30 | 30.99% |
| 2004-03-31 | 30.39% |
| 2003-12-31 | 33.39% |
| 2003-09-30 | 29.81% |
| 2003-06-30 | 32.75% |
| 2003-03-31 | 30.90% |
| 2002-12-31 | 27.56% |
| 2002-09-30 | 25.45% |
| 2002-06-30 | 28.78% |
Related Metrics
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green